Statement of Changes in Beneficial Ownership (4)
April 13 2020 - 6:24PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Landry Robert E |
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC.
[
REGN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP Finance CFO |
(Last)
(First)
(Middle)
777 OLD SAW MILL RIVER ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
4/9/2020 |
(Street)
TARRYTOWN, NY 10591
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 4/9/2020 | | M(1) | | 3500 | A | $272.7 | 27873 | D | |
Common Stock | 4/9/2020 | | F(1) | | 2672 | D | $508.25 | 25201 | D | |
Common Stock | 4/13/2020 | | S(1) | | 99 | D | $505.6 | 25102 | D | |
Common Stock | 4/13/2020 | | S(1) | | 38 | D | $506.24 | 25064 | D | |
Common Stock | 4/13/2020 | | S(1) | | 30 | D | $507.45 (2) | 25034 | D | |
Common Stock | 4/13/2020 | | S(1) | | 115 | D | $508.54 (3) | 24919 | D | |
Common Stock | 4/13/2020 | | S(1) | | 170 | D | $509.45 (4) | 24749 | D | |
Common Stock | 4/13/2020 | | S(1) | | 143 | D | $510.43 (5) | 24606 | D | |
Common Stock | 4/13/2020 | | S(1) | | 156 | D | $511.59 (6) | 24450 | D | |
Common Stock | 4/13/2020 | | S(1) | | 31 | D | $512.58 (7) | 24419 | D | |
Common Stock | 4/13/2020 | | S(1) | | 46 | D | $517.71 | 24373 | D | |
Common Stock | | | | | | | | 172 | I | By 401(k) Plan |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Non-Qualified Stock Option (right to buy) | $272.7 | 4/9/2020 | | M (1) | | | 3500 | (8) | 9/9/2023 | Common Stock | 3500 | $0.0 | 39000 | D | |
Explanation of Responses: |
(1) | Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). |
(2) | Represents volume-weighted average price of sales of 30 shares of Company stock on April 13, 2020 at prices ranging from $507.44 to $507.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price. |
(3) | Represents volume-weighted average price of sales of 115 shares of Company stock on April 13, 2020 at prices ranging from $508.24 to $508.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price. |
(4) | Represents volume-weighted average price of sales of 170 shares of Company stock on April 13, 2020 at prices ranging from $509.03 to $509.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price. |
(5) | Represents volume-weighted average price of sales of 143 shares of Company stock on April 13, 2020 at prices ranging from $510.11 to $510.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price. |
(6) | Represents volume-weighted average price of sales of 156 shares of Company stock on April 13, 2020 at prices ranging from $511.23 to $511.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price. |
(7) | Represents volume-weighted average price of sales of 31 shares of Company stock on April 13, 2020 at prices ranging from $512.01 to $512.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price. |
(8) | The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Landry Robert E 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 |
|
| EVP Finance CFO |
|
Signatures
|
/s/**Robert E. Landry | | 4/20/2020 |
**Signature of Reporting Person | Date |
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024